JP4619372B2 - 改良された対照区画を有する免疫学的試験素子 - Google Patents
改良された対照区画を有する免疫学的試験素子 Download PDFInfo
- Publication number
- JP4619372B2 JP4619372B2 JP2007005044A JP2007005044A JP4619372B2 JP 4619372 B2 JP4619372 B2 JP 4619372B2 JP 2007005044 A JP2007005044 A JP 2007005044A JP 2007005044 A JP2007005044 A JP 2007005044A JP 4619372 B2 JP4619372 B2 JP 4619372B2
- Authority
- JP
- Japan
- Prior art keywords
- analyte
- conjugate
- compartment
- binding partner
- test
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 238000012360 testing method Methods 0.000 title claims abstract description 85
- 230000001900 immune effect Effects 0.000 title claims description 13
- 239000012491 analyte Substances 0.000 claims abstract description 107
- 238000001514 detection method Methods 0.000 claims abstract description 62
- 239000007788 liquid Substances 0.000 claims abstract description 18
- 239000003153 chemical reaction reagent Substances 0.000 claims abstract description 15
- 230000027455 binding Effects 0.000 claims description 54
- 238000000034 method Methods 0.000 claims description 10
- 230000003287 optical effect Effects 0.000 claims description 5
- 230000000007 visual effect Effects 0.000 claims description 4
- 238000003018 immunoassay Methods 0.000 abstract description 2
- 239000003446 ligand Substances 0.000 abstract 4
- 239000000523 sample Substances 0.000 description 30
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 26
- 239000010931 gold Substances 0.000 description 25
- 229910052737 gold Inorganic materials 0.000 description 25
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 23
- 229960002685 biotin Drugs 0.000 description 21
- 239000011616 biotin Substances 0.000 description 21
- 239000000243 solution Substances 0.000 description 16
- 101100537532 Rattus norvegicus Tnni3 gene Proteins 0.000 description 15
- 108010090804 Streptavidin Proteins 0.000 description 14
- 230000007246 mechanism Effects 0.000 description 14
- 235000020958 biotin Nutrition 0.000 description 13
- 239000000427 antigen Substances 0.000 description 9
- 102000036639 antigens Human genes 0.000 description 9
- 108091007433 antigens Proteins 0.000 description 9
- 239000012528 membrane Substances 0.000 description 9
- 210000004369 blood Anatomy 0.000 description 8
- 239000008280 blood Substances 0.000 description 8
- 230000000694 effects Effects 0.000 description 8
- 238000005259 measurement Methods 0.000 description 8
- 238000000926 separation method Methods 0.000 description 7
- 239000002699 waste material Substances 0.000 description 7
- 210000003743 erythrocyte Anatomy 0.000 description 6
- 239000000203 mixture Substances 0.000 description 6
- 108090000765 processed proteins & peptides Proteins 0.000 description 6
- 239000008279 sol Substances 0.000 description 6
- 239000000835 fiber Substances 0.000 description 5
- 229920006395 saturated elastomer Polymers 0.000 description 5
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 4
- 239000004372 Polyvinyl alcohol Substances 0.000 description 4
- 108010065729 Troponin I Proteins 0.000 description 4
- 238000003556 assay Methods 0.000 description 4
- UCMIRNVEIXFBKS-UHFFFAOYSA-N beta-alanine Chemical compound NCCC(O)=O UCMIRNVEIXFBKS-UHFFFAOYSA-N 0.000 description 4
- 229940098773 bovine serum albumin Drugs 0.000 description 4
- 238000005470 impregnation Methods 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- 239000002245 particle Substances 0.000 description 4
- 229920002451 polyvinyl alcohol Polymers 0.000 description 4
- 102000014914 Carrier Proteins Human genes 0.000 description 3
- 108010078791 Carrier Proteins Proteins 0.000 description 3
- 239000000020 Nitrocellulose Substances 0.000 description 3
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 3
- 229930006000 Sucrose Natural products 0.000 description 3
- 150000001413 amino acids Chemical class 0.000 description 3
- 230000007423 decrease Effects 0.000 description 3
- 238000011156 evaluation Methods 0.000 description 3
- 239000012634 fragment Substances 0.000 description 3
- 239000003365 glass fiber Substances 0.000 description 3
- 229920001220 nitrocellulos Polymers 0.000 description 3
- 229920000728 polyester Polymers 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 230000009870 specific binding Effects 0.000 description 3
- 239000005720 sucrose Substances 0.000 description 3
- SHIBSTMRCDJXLN-UHFFFAOYSA-N Digoxigenin Natural products C1CC(C2C(C3(C)CCC(O)CC3CC2)CC2O)(O)C2(C)C1C1=CC(=O)OC1 SHIBSTMRCDJXLN-UHFFFAOYSA-N 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 229920001213 Polysorbate 20 Polymers 0.000 description 2
- 229920000297 Rayon Polymers 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 239000007983 Tris buffer Substances 0.000 description 2
- 101710128251 Troponin I, cardiac muscle Proteins 0.000 description 2
- 102100036859 Troponin I, cardiac muscle Human genes 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 229940000635 beta-alanine Drugs 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 230000000747 cardiac effect Effects 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 238000004587 chromatography analysis Methods 0.000 description 2
- QONQRTHLHBTMGP-UHFFFAOYSA-N digitoxigenin Natural products CC12CCC(C3(CCC(O)CC3CC3)C)C3C11OC1CC2C1=CC(=O)OC1 QONQRTHLHBTMGP-UHFFFAOYSA-N 0.000 description 2
- SHIBSTMRCDJXLN-KCZCNTNESA-N digoxigenin Chemical compound C1([C@@H]2[C@@]3([C@@](CC2)(O)[C@H]2[C@@H]([C@@]4(C)CC[C@H](O)C[C@H]4CC2)C[C@H]3O)C)=CC(=O)OC1 SHIBSTMRCDJXLN-KCZCNTNESA-N 0.000 description 2
- 230000004064 dysfunction Effects 0.000 description 2
- -1 fleece Substances 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- 239000004816 latex Substances 0.000 description 2
- 229920000126 latex Polymers 0.000 description 2
- 239000011159 matrix material Substances 0.000 description 2
- 210000002381 plasma Anatomy 0.000 description 2
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 2
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 2
- 238000009597 pregnancy test Methods 0.000 description 2
- 239000002964 rayon Substances 0.000 description 2
- 238000011084 recovery Methods 0.000 description 2
- 238000002310 reflectometry Methods 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- LWIHDJKSTIGBAC-UHFFFAOYSA-K tripotassium phosphate Chemical compound [K+].[K+].[K+].[O-]P([O-])([O-])=O LWIHDJKSTIGBAC-UHFFFAOYSA-K 0.000 description 2
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 2
- 238000011144 upstream manufacturing Methods 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 description 1
- IEQAICDLOKRSRL-UHFFFAOYSA-N 2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-(2-dodecoxyethoxy)ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethanol Chemical compound CCCCCCCCCCCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO IEQAICDLOKRSRL-UHFFFAOYSA-N 0.000 description 1
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
- SLXKOJJOQWFEFD-UHFFFAOYSA-N 6-aminohexanoic acid Chemical compound NCCCCCC(O)=O SLXKOJJOQWFEFD-UHFFFAOYSA-N 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- IMROMDMJAWUWLK-UHFFFAOYSA-N Ethenol Chemical compound OC=C IMROMDMJAWUWLK-UHFFFAOYSA-N 0.000 description 1
- 239000007995 HEPES buffer Substances 0.000 description 1
- 101000851334 Homo sapiens Troponin I, cardiac muscle Proteins 0.000 description 1
- 239000004831 Hot glue Substances 0.000 description 1
- 108010021625 Immunoglobulin Fragments Proteins 0.000 description 1
- 102000008394 Immunoglobulin Fragments Human genes 0.000 description 1
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- 102400001263 NT-proBNP Human genes 0.000 description 1
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 description 1
- 102000004987 Troponin T Human genes 0.000 description 1
- 108090001108 Troponin T Proteins 0.000 description 1
- 206010057362 Underdose Diseases 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 239000002250 absorbent Substances 0.000 description 1
- 230000002745 absorbent Effects 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 238000013019 agitation Methods 0.000 description 1
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- 235000001014 amino acid Nutrition 0.000 description 1
- 229960002684 aminocaproic acid Drugs 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000008275 binding mechanism Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000006287 biotinylation Effects 0.000 description 1
- 238000007413 biotinylation Methods 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 238000013098 chemical test method Methods 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
- 229960002433 cysteine Drugs 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000002405 diagnostic procedure Methods 0.000 description 1
- 238000000502 dialysis Methods 0.000 description 1
- KZNICNPSHKQLFF-UHFFFAOYSA-N dihydromaleimide Natural products O=C1CCC(=O)N1 KZNICNPSHKQLFF-UHFFFAOYSA-N 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 239000011888 foil Substances 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 238000012812 general test Methods 0.000 description 1
- 230000007274 generation of a signal involved in cell-cell signaling Effects 0.000 description 1
- 150000002343 gold Chemical class 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 230000000984 immunochemical effect Effects 0.000 description 1
- 238000003365 immunocytochemistry Methods 0.000 description 1
- 238000010324 immunological assay Methods 0.000 description 1
- 230000007233 immunological mechanism Effects 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 230000007257 malfunction Effects 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 238000010369 molecular cloning Methods 0.000 description 1
- 230000006911 nucleation Effects 0.000 description 1
- 238000010899 nucleation Methods 0.000 description 1
- 239000013610 patient sample Substances 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 238000003752 polymerase chain reaction Methods 0.000 description 1
- 229910000160 potassium phosphate Inorganic materials 0.000 description 1
- 235000011009 potassium phosphates Nutrition 0.000 description 1
- 230000035935 pregnancy Effects 0.000 description 1
- 108010008064 pro-brain natriuretic peptide (1-76) Proteins 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 210000003296 saliva Anatomy 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- 238000010532 solid phase synthesis reaction Methods 0.000 description 1
- 125000006850 spacer group Chemical group 0.000 description 1
- 229910001220 stainless steel Inorganic materials 0.000 description 1
- 239000010935 stainless steel Substances 0.000 description 1
- 229960002317 succinimide Drugs 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 210000004243 sweat Anatomy 0.000 description 1
- HRXKRNGNAMMEHJ-UHFFFAOYSA-K trisodium citrate Chemical compound [Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O HRXKRNGNAMMEHJ-UHFFFAOYSA-K 0.000 description 1
- 229940038773 trisodium citrate Drugs 0.000 description 1
- 238000000108 ultra-filtration Methods 0.000 description 1
- 230000002485 urinary effect Effects 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
Images
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
- G01N33/54366—Apparatus specially adapted for solid-phase testing
- G01N33/54386—Analytical elements
- G01N33/54387—Immunochromatographic test strips
- G01N33/54388—Immunochromatographic test strips based on lateral flow
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
- G01N33/54306—Solid-phase reaction mechanisms
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
- G01N33/54366—Apparatus specially adapted for solid-phase testing
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01L—CHEMICAL OR PHYSICAL LABORATORY APPARATUS FOR GENERAL USE
- B01L2300/00—Additional constructional details
- B01L2300/08—Geometry, shape and general structure
- B01L2300/0809—Geometry, shape and general structure rectangular shaped
- B01L2300/0825—Test strips
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01L—CHEMICAL OR PHYSICAL LABORATORY APPARATUS FOR GENERAL USE
- B01L2400/00—Moving or stopping fluids
- B01L2400/04—Moving fluids with specific forces or mechanical means
- B01L2400/0403—Moving fluids with specific forces or mechanical means specific forces
- B01L2400/0406—Moving fluids with specific forces or mechanical means specific forces capillary forces
Landscapes
- Health & Medical Sciences (AREA)
- Immunology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Medicinal Chemistry (AREA)
- Analytical Chemistry (AREA)
- Cell Biology (AREA)
- Pathology (AREA)
- Food Science & Technology (AREA)
- Biotechnology (AREA)
- Physics & Mathematics (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- General Physics & Mathematics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Investigating Or Analysing Materials By The Use Of Chemical Reactions (AREA)
Description
コンジュゲート区画(または試薬区画)は通常、試験素子中または試験素子上のサンプル付加区画と検出区画との間に位置する。サンプル付加区画およびコンジュゲート区画は同一とすることもできる。コンジュゲート区画はアナライトに対する免疫学的結合パートナー(一般的に抗体またはそのフラグメント)を保持し、これは再溶解および再分離することができ、従って、サンプル液によって移動させることができる。その結合パートナーは通常、シグナル生成酵素またはいわゆる直接標識(例えば、金または着色ラテックス粒子、蛍光標識など)に結合されている(いわゆるコンジュゲート)。
検出区画と廃液部との間に位置する対照区画は、不可逆的に固定化されたアナライト(またはアナライト類似体)を保持する。過剰な結合パートナー−標識コンジュゲートは固定化されたアナライトまたはアナライト類似体に結合し、それにより対照ラインにおいて検出可能なシグナルをもたらす。
検出区画と廃液部との間に位置する対照区画は、コンジュゲート抗体に対するポリハプテンを保持する。
対照区画は抗体−標識コンジュゲートに対する抗体を保持する。この対照区画の原理は妊娠テストストリップにおいて非常に広く普及している。
対照ラインは、コンジュゲートの「独立した標識」に対する結合パートナーを保持する。
図1に従ったテストストリップが製造される。
対照ライン8の組成だけが異なる以下の3つのテストストリップの変形形態を、a)に記載された方法に従って製造した。対照ライン8を作製するための溶液は、以下の3つの変形形態で構成された。すなわち、
変形形態1:1mg/ml ポリハプテン[PH,TnI(27−43)];古典的な対照ラインを有するテストストリップ、
変形形態2:1mg/mlストレプトアビジン;対照ラインとして第二の検出ライン試薬を有するテストストリップ、
変形形態3:1mg/mlポリハプテンおよび1mg/mlストレプトアビジン;本発明の対照ラインを有するテストストリップ、である。
予想通り、検出ラインの強度は、最初はアナライト濃度の増加とともに増加し(1ng/ml〜50 ng/ml cTnIでの反射率の値の減少)、最大強度(18%反射率、すなわち発色飽和)を過ぎた後、著しく高いアナライト濃度ではサンドイッチ方式により引き起こされる高濃度でのフック効果のため再度減少する。前記の高濃度でのフック効果は、1000ng/ml cTnIでテストストリップの検出ラインにおいてほぼ100%の反射率の値(視覚的に陰性)を示し、従って偽陰性の検出ラインを生じる。
アナライトの非存在下では、金コンジュゲートは、ポリハプテン(aa27−43)へのM155抗体の結合によって、ほぼ定量的に対照ラインに蓄積する(20%反射率)。一方、アナライト濃度が増加するに従って、対照ラインの発色強度は減少する。これは、金コンジュゲートの大部分がサンドイッチ複合体の形で検出ラインに捕捉されるため、および、検出ラインに捕捉されない金コンジュゲートの一部は存在するアナライト濃度の増加によってすでに飽和し、従って、もはや対照ラインのポリハプテンに十分結合できないためである。この場合、クロマトグラフ分離された金コンジュゲートは、検出ラインおよび対照ラインを超えて、その下流に位置する廃液用フリース2に移動する。
対照ラインと見なされる第二のストレプトアビジン検出ラインは、アナライトの非存在下では、サンドイッチ複合体が形成されないため(対照ラインとしてのその機能に関して)当然ながら機能しない。従って、第一検出ラインがアナライトの存在しないことを正しく反映していても、試験結果は無効とみなされるであろう。
表中に測定および視覚的分類によって示されるように、この対照ラインは(ポリハプテン金コンジュゲート機構によって)アナライトの非存在下で試験結果が正しいことを示唆する。
B 赤血球分離区画
C 検出区画
D 吸引区画
1 支持材
2 吸引フリース(廃液部)
3 検出ラインおよび対照ラインを含むクロマトグラフィーメンブレン
4 赤血球分離用マトリックス(血液分離用フリース)
5 金コンジュゲートフリース(標識化コンジュゲート)
6 ビオチンコンジュゲートフリース(タグ付きコンジュゲート)
7 検出ライン(固定化されたポリストレプトアビジン)
8 対照ライン
Claims (2)
- 液体サンプルに由来するアナライト測定用の免疫学的サンドイッチ試験の実施のための試験素子であって、
アナライト結合パートナーと標識とのコンジュゲートを保持する試薬区画であって、該標識は、視覚的、光学的もしくは電気化学的手段により直接的または間接的に検出可能であり、該コンジュゲートは液体サンプルによって溶解可能であるもの;
アナライトまたはアナライトを含有する複合体に対する解離不可能に固定化された結合パートナーを保持する検出区画;および
アナライト結合パートナーと標識とのコンジュゲートに対する解離不可能に固定化された結合パートナーを保持する対照区画
を有し、該対照区画が、アナライトまたはアナライトを含有する複合体に対する1以上の解離不可能に固定化された結合パートナーをさらに保持することを特徴とする、上記試験素子。 - 液体サンプル由来のアナライトを検出するための方法であって、
請求項1に記載の試験素子にサンプルを付加し、
該サンプル中に存在すれば、アナライトを標識化コンジュゲートと反応させてアナライト−コンジュゲート複合体を形成させ、
検出区画中で、該アナライト−コンジュゲート複合体を、アナライトまたはアナライトを含有する複合体に対する解離不可能に固定化された結合パートナーに結合させ、
対照区画中で、アナライトと反応していない標識化コンンジュゲートを、コンジュゲートに対する解離不可能に固定化された結合パートナーと結合させ、かつ
対照区画中で、アナライト−コンジュゲート複合体を、アナライトまたはアナライトを含有する複合体に対する解離不可能に固定化された結合パートナーに結合させる、上記方法。
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP06000791 | 2006-01-14 |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2007187664A JP2007187664A (ja) | 2007-07-26 |
JP4619372B2 true JP4619372B2 (ja) | 2011-01-26 |
Family
ID=37835258
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2007005044A Active JP4619372B2 (ja) | 2006-01-14 | 2007-01-12 | 改良された対照区画を有する免疫学的試験素子 |
Country Status (9)
Country | Link |
---|---|
US (5) | US20070184506A1 (ja) |
EP (1) | EP1808696B1 (ja) |
JP (1) | JP4619372B2 (ja) |
CN (1) | CN101000343B (ja) |
AT (1) | ATE425458T1 (ja) |
CA (1) | CA2573749C (ja) |
DE (1) | DE502007000483D1 (ja) |
ES (1) | ES2322297T3 (ja) |
HK (1) | HK1101200A1 (ja) |
Families Citing this family (23)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8614101B2 (en) * | 2008-05-20 | 2013-12-24 | Rapid Pathogen Screening, Inc. | In situ lysis of cells in lateral flow immunoassays |
US8669052B2 (en) * | 2008-06-10 | 2014-03-11 | Rapid Pathogen Screening, Inc. | Lateral flow nucleic acid detector |
US8815609B2 (en) | 2008-05-20 | 2014-08-26 | Rapid Pathogen Screening, Inc. | Multiplanar lateral flow assay with diverting zone |
US9068981B2 (en) | 2009-12-04 | 2015-06-30 | Rapid Pathogen Screening, Inc. | Lateral flow assays with time delayed components |
US20130196310A1 (en) | 2008-05-20 | 2013-08-01 | Rapid Pathogen Screening, Inc. | Method and Device for Combined Detection of Viral and Bacterial Infections |
US9910036B2 (en) | 2008-05-20 | 2018-03-06 | Rapid Pathogen Screening, Inc. | Method and device for combined detection of viral and bacterial infections |
US8609433B2 (en) | 2009-12-04 | 2013-12-17 | Rapid Pathogen Screening, Inc. | Multiplanar lateral flow assay with sample compressor |
US8962260B2 (en) | 2008-05-20 | 2015-02-24 | Rapid Pathogen Screening, Inc. | Method and device for combined detection of viral and bacterial infections |
US20110086359A1 (en) | 2008-06-10 | 2011-04-14 | Rapid Pathogen Screening, Inc. | Lateral flow assays |
BRPI0914128B8 (pt) * | 2008-06-30 | 2021-07-27 | Sekisui Medical Co Ltd | tira de ensaio de ligação, dispositivo compreendendo a tira de ensaio de ligação, e, método de ensaio de ligação |
EP2194381B1 (de) * | 2008-12-03 | 2015-12-02 | Roche Diagnostics GmbH | Testelement mit kombinierter Kontroll- und Kalibrationszone |
WO2010129302A1 (en) * | 2009-04-28 | 2010-11-11 | Innovative Laboratory Technologies, Inc. | Lateral-flow immuno-chromatographic assay devices |
WO2011069031A2 (en) * | 2009-12-04 | 2011-06-09 | Rapid Pathogen Screening, Inc. | Multiplanar lateral flow assay with sample compressor |
FR2967497B1 (fr) * | 2010-11-17 | 2014-12-12 | Biomerieux Sa | Dispositif et procede pour immunoessais |
JP5917201B2 (ja) * | 2012-03-02 | 2016-05-11 | 田中貴金属工業株式会社 | イムノクロマトグラフィー用試験ストリップ |
JP5545683B2 (ja) * | 2012-03-29 | 2014-07-09 | 株式会社Lsiメディエンス | イムノクロマトグラフ用試験具 |
JP5541748B2 (ja) * | 2012-03-29 | 2014-07-09 | 株式会社Lsiメディエンス | アビジン−ビオチン連結標識試薬を用いたイムノクロマトグラフ用試験具及びその利用 |
KR101952957B1 (ko) * | 2012-06-20 | 2019-02-28 | 주식회사 미코바이오메드 | 센서 스트립 |
FR3009386A1 (fr) * | 2013-08-02 | 2015-02-06 | Biomerieux Sa | Dispositif et procede d'analyses biologiques |
US10808287B2 (en) | 2015-10-23 | 2020-10-20 | Rapid Pathogen Screening, Inc. | Methods and devices for accurate diagnosis of infections |
CN107918015A (zh) * | 2017-07-14 | 2018-04-17 | 王镕 | 免疫层析半定量试纸条、试剂盒以及检测方法 |
WO2020033235A1 (en) * | 2018-08-06 | 2020-02-13 | Becton, Dickinson And Company | Lateral flow immunoassay device with separation membrane |
AU2020383527A1 (en) * | 2019-11-15 | 2022-06-09 | Massachusetts Institute Of Technology | Device and method for analyte detection |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2000097941A (ja) * | 1998-09-18 | 2000-04-07 | Matsushita Electric Ind Co Ltd | 免疫クロマトグラフィーのためのキット |
WO2004109285A1 (en) * | 2003-06-03 | 2004-12-16 | Bayer Healthcare Llc | Native analyte as reference in lateral flow assays |
JP2007506115A (ja) * | 2003-09-22 | 2007-03-15 | クイデル コーポレーション | 試料中の複数分析物の検出装置 |
JP2007537428A (ja) * | 2004-05-12 | 2007-12-20 | エフ.ホフマン−ラ ロシュ アーゲー | 特異的結合反応型試験素子、特に免疫試験素子のダイナミック測定レンジを大きくするための方法 |
Family Cites Families (25)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4595661A (en) * | 1983-11-18 | 1986-06-17 | Beckman Instruments, Inc. | Immunoassays and kits for use therein which include low affinity antibodies for reducing the hook effect |
DE3445816C1 (de) * | 1984-12-15 | 1986-06-12 | Behringwerke Ag, 3550 Marburg | Flaechenfoermiges diagnostisches Mittel |
ATE195022T1 (de) | 1987-04-27 | 2000-08-15 | Unilever Nv | Spezifische bindungstestverfahren |
DE3802366A1 (de) * | 1988-01-27 | 1989-08-10 | Boehringer Mannheim Gmbh | Traegervlies fuer abloesbar impraegnierte reagenzien |
US5939272A (en) * | 1989-01-10 | 1999-08-17 | Biosite Diagnostics Incorporated | Non-competitive threshold ligand-receptor assays |
JPH05504841A (ja) * | 1990-09-14 | 1993-07-22 | バイオサイト・ダイアグノスティックス・インコーポレイテッド | リガンドレセプター及びリガンドのコンプレックスに対する抗体及びリガンド―レセプターアッセーでのそれらの用途 |
US5296347A (en) * | 1991-02-08 | 1994-03-22 | Ciba Corning Diagnostics Corp. | Bridge immunoassay |
US5451504A (en) * | 1991-07-29 | 1995-09-19 | Serex, Inc. | Method and device for detecting the presence of analyte in a sample |
US6156270A (en) * | 1992-05-21 | 2000-12-05 | Biosite Diagnostics, Inc. | Diagnostic devices and apparatus for the controlled movement of reagents without membranes |
US5968839A (en) * | 1996-05-13 | 1999-10-19 | Metrika, Inc. | Method and device producing a predetermined distribution of detectable change in assays |
GB9709821D0 (en) * | 1997-05-15 | 1997-07-09 | Clinical Diagnostic Chemicals | Allergy assay |
US6183972B1 (en) * | 1998-07-27 | 2001-02-06 | Bayer Corporation | Method for the determination of analyte concentration in a lateral flow sandwich immunoassay exhibiting high-dose hook effect |
WO2000031538A1 (en) * | 1998-11-23 | 2000-06-02 | Praxsys Biosystems, Inc. | Improved lateral flow assays |
US6528323B1 (en) * | 1999-06-14 | 2003-03-04 | Praxsys Biosystems, Inc. | Bidirectional lateral flow test strip and method |
DE10009503A1 (de) * | 2000-02-29 | 2001-08-30 | Roche Diagnostics Gmbh | Verfahren zur Immobilisierung von Konjugaten in diagnostischen Tests |
DE10064827A1 (de) * | 2000-12-22 | 2002-06-27 | Dade Behring Marburg Gmbh | Nachweisverfahren |
FR2853077B1 (fr) * | 2003-03-28 | 2005-12-30 | Vedalab | Procedes immunochromatographiques en phase solide |
US7943395B2 (en) * | 2003-11-21 | 2011-05-17 | Kimberly-Clark Worldwide, Inc. | Extension of the dynamic detection range of assay devices |
DE10355731A1 (de) * | 2003-11-28 | 2005-06-30 | Roche Diagnostics Gmbh | Analytischer Sandwichtest zur Bestimmung von NT-proBNP |
US7439079B2 (en) * | 2005-04-29 | 2008-10-21 | Kimberly-Clark Worldwide, Inc. | Assay devices having detection capabilities within the hook effect region |
US7803319B2 (en) * | 2005-04-29 | 2010-09-28 | Kimberly-Clark Worldwide, Inc. | Metering technique for lateral flow assay devices |
FR2890173B1 (fr) * | 2005-08-23 | 2008-02-22 | Vedalab Sa | Dispositif de determination d'un analyte dans un echantillon liquide par un test sandwich et un test de competition |
US7829347B2 (en) * | 2005-08-31 | 2010-11-09 | Kimberly-Clark Worldwide, Inc. | Diagnostic test kits with improved detection accuracy |
US7279136B2 (en) * | 2005-12-13 | 2007-10-09 | Takeuchi James M | Metering technique for lateral flow assay devices |
US7745158B2 (en) * | 2005-12-14 | 2010-06-29 | Kimberly-Clark Worldwide, Inc. | Detection of secreted aspartyl proteases from Candida species |
-
2007
- 2007-01-11 ES ES07000476T patent/ES2322297T3/es active Active
- 2007-01-11 DE DE502007000483T patent/DE502007000483D1/de active Active
- 2007-01-11 AT AT07000476T patent/ATE425458T1/de active
- 2007-01-11 CN CN2007100012668A patent/CN101000343B/zh active Active
- 2007-01-11 EP EP07000476A patent/EP1808696B1/de active Active
- 2007-01-12 US US11/622,515 patent/US20070184506A1/en not_active Abandoned
- 2007-01-12 JP JP2007005044A patent/JP4619372B2/ja active Active
- 2007-01-12 CA CA2573749A patent/CA2573749C/en not_active Expired - Fee Related
- 2007-08-21 HK HK07109099.4A patent/HK1101200A1/xx not_active IP Right Cessation
-
2010
- 2010-09-14 US US12/881,651 patent/US8951806B2/en active Active
- 2010-11-01 US US12/917,124 patent/US20110091914A1/en not_active Abandoned
-
2014
- 2014-12-29 US US14/584,382 patent/US9528986B2/en active Active
-
2016
- 2016-11-10 US US15/348,582 patent/US10429382B2/en active Active
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2000097941A (ja) * | 1998-09-18 | 2000-04-07 | Matsushita Electric Ind Co Ltd | 免疫クロマトグラフィーのためのキット |
WO2004109285A1 (en) * | 2003-06-03 | 2004-12-16 | Bayer Healthcare Llc | Native analyte as reference in lateral flow assays |
JP2007526443A (ja) * | 2003-06-03 | 2007-09-13 | バイエル・ヘルスケア・エルエルシー | ラテラルフローアッセイの基準としての天然分析物 |
JP2007506115A (ja) * | 2003-09-22 | 2007-03-15 | クイデル コーポレーション | 試料中の複数分析物の検出装置 |
JP2007537428A (ja) * | 2004-05-12 | 2007-12-20 | エフ.ホフマン−ラ ロシュ アーゲー | 特異的結合反応型試験素子、特に免疫試験素子のダイナミック測定レンジを大きくするための方法 |
Also Published As
Publication number | Publication date |
---|---|
US9528986B2 (en) | 2016-12-27 |
CA2573749A1 (en) | 2007-07-14 |
US8951806B2 (en) | 2015-02-10 |
US10429382B2 (en) | 2019-10-01 |
HK1101200A1 (en) | 2007-11-30 |
US20110091914A1 (en) | 2011-04-21 |
US20150140582A1 (en) | 2015-05-21 |
US20100330705A1 (en) | 2010-12-30 |
US20170059564A1 (en) | 2017-03-02 |
DE502007000483D1 (de) | 2009-04-23 |
ATE425458T1 (de) | 2009-03-15 |
JP2007187664A (ja) | 2007-07-26 |
CN101000343A (zh) | 2007-07-18 |
ES2322297T3 (es) | 2009-06-18 |
CN101000343B (zh) | 2012-11-14 |
US20070184506A1 (en) | 2007-08-09 |
EP1808696A1 (de) | 2007-07-18 |
CA2573749C (en) | 2010-11-16 |
EP1808696B1 (de) | 2009-03-11 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP4619372B2 (ja) | 改良された対照区画を有する免疫学的試験素子 | |
US6998246B2 (en) | Method for immobilizing conjugates in diagnostic tests | |
JP4846573B2 (ja) | 基準としての天然分析物を有するラテラルフローアッセイ装置および方法 | |
US7344893B2 (en) | Immuno-gold lateral flow assay | |
US8093057B2 (en) | System for quantitative measurement of glycohemoglobin and method for measuring glycohemoglobin | |
JP3358737B2 (ja) | 改良された投与量応答曲線を有するアッセイ | |
EP0303110B1 (en) | Immunodiagnostic device and method | |
CA2566040C (en) | Method for increasing the dynamic measuring range of test elements, especially immunological test elements, that are based on specific binding reactions | |
JP5173808B2 (ja) | 横向き移動でのイムノクロマトの手段による検体アッセイ | |
JP3005303B2 (ja) | 測定装置 | |
EP1938102A2 (en) | Improved target ligand detection | |
AU2019290399A1 (en) | Systems, devices, and methods for amplifying signals of a lateral flow assay | |
KR20160120675A (ko) | 래피드 정량 진단 키트 | |
JP4437211B2 (ja) | 免疫クロマトグラフィーを用いた測定方法およびそれに用いる検体分析用具 | |
JP4109245B2 (ja) | 分析装置及び分析方法 | |
KR20150111391A (ko) | 면역크로마토그래피 분석용 디바이스 | |
JPH1048212A (ja) | 免疫クロマトグラフィー試験片を用いて分析対象物を測定する方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20091224 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20100112 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20100331 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20100405 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20101019 |
|
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20101026 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20131105 Year of fee payment: 3 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 4619372 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |